ring
major
pharmacophor
system
among
nitrogencontain
heterocycl
fivememb
heterocycl
motif
three
nitrogen
heteroatom
prepar
easili
use
click
chemistri
copperor
rutheniumcatalys
azidealkyn
cycloaddit
reaction
recent
linker
properti
demonstr
novel
class
hybrid
conjug
synthesis
evalu
lead
compound
divers
biolog
target
lead
compound
demonstr
anticanc
antimicrobi
antitubercular
antivir
antidiabet
antimalari
antileishmani
neuroprotect
agent
present
review
summaris
advanc
lead
compound
hybrid
conjug
relat
heterocycl
medicin
chemistri
publish
review
use
scientist
research
field
organ
synthesi
medicin
chemistri
phytochemistri
pharmacolog
gener
synthet
rout
use
click
chemistri
describ
scheme
popular
rout
cu
catalys
huisgen
cycloaddit
http
doi
heterocycl
organ
chemistri
one
import
wellstudi
branch
medicin
chemistri
import
featur
heterocycl
bioactiv
compound
variou
constitu
heteroatom
includ
nitrogen
sulphur
oxygen
other
heteroatom
directli
affect
reactiv
target
skeleton
activ
toxicolog
compound
interact
target
drug
differ
target
inhibitor
well
abl
influenc
metabol
pharmacokinet
promis
heterocycl
compound
azol
fivememb
nitrogen
heterocycl
nitrogencontain
azol
skeleton
offer
advantag
two
nitrogen
heteroatom
ring
import
effect
structur
modif
biolog
interact
past
decad
chemistri
biolog
azol
deriv
emerg
popular
topic
perform
search
scopu
databas
decemb
use
azol
imidazol
pyrazol
triazol
tetrazol
pentazol
keyword
identifi
differ
publish
report
found
triazol
motif
frequent
studi
fig
particularli
note
advanc
click
chemistri
coppercatalys
azidealkyn
cycloaddit
cuaac
reaction
variou
synthet
methodolog
scaffold
eg
deriv
hybrid
conjug
use
medicin
chemistri
fig
variou
biolog
screen
conduct
led
identif
anticanc
antimicrobi
antiinfect
antioxid
properti
studi
hybrid
moreov
triazolelink
deriv
suggest
affect
adenosin
diphosph
ribosyl
biolog
use
wide
peptid
mimic
transamid
bond
despit
hazard
effect
nativ
peptid
activ
addit
core
provid
divers
pharmacophor
properti
hybrid
commonli
consid
lead
compound
contain
fuse
ring
thu
view
factor
recent
focu
research
compound
discuss
highlight
divers
biolog
activ
hybrid
conjug
relat
compound
lead
medicin
chemistri
base
articl
publish
confirm
triazol
compound
may
inhibit
affect
migrat
cell
anoth
melampomagnolid
btriazol
conjug
compound
fig
effect
potent
sever
cancer
cell
line
includ
leukaemia
gi
colon
gi
melanoma
gi
renal
gi
ovarian
gi
prostat
gi
breast
gi
cancer
cell
line
subpanel
investig
indic
triazol
compound
potent
inhibitor
nuclear
factor
nf
kb
cell
prolifer
cell
line
moreov
treatment
cell
deriv
decreas
dna
bind
activ
nfkb
inhibit
phosphoryl
mediat
inhibitor
nfkb
kinas
ikk
b
increas
basal
level
via
inhibit
substanti
nfkb
activ
turnov
yu
et
al
synthesis
seri
hybrid
screen
anticanc
potenti
two
type
cancer
cell
hybrid
display
modest
cytotox
toward
cell
line
particularli
hypox
condit
howev
hybrid
fig
activ
cell
normox
ic
hypoxia
ic
furthermor
hybrid
arrest
cell
phase
inhibit
migrat
tumour
cell
caus
larg
reduc
mitochondri
membran
capabl
lead
apoptosi
cell
diterpenoid
moieti
jiyuan
oridonin
test
antiprolif
properti
deriv
fig
contain
triazol
ring
also
display
better
antiprolif
activ
ic
valu
cell
line
breast
cancer
cell
line
test
cell
moreov
ic
valu
also
evalu
cancer
cell
cellular
mechanist
studi
demonstr
compound
arrest
cell
cycl
phase
induc
potent
apoptosi
cell
line
also
inhibit
coloni
migrat
format
wnt
signal
pathway
cell
anoth
two
seri
entkauren
diterpenoid
deriv
screen
antiprolif
properti
four
cancer
cell
line
cell
compound
fig
display
highli
anticanc
potenti
test
cell
line
ic
valu
cell
line
respect
posit
control
oridonin
confirm
benefici
heterocycl
moieti
affect
cytotox
triazolecontain
hybrid
investig
anticanc
mechan
show
increas
reactiv
oxygen
speci
ro
level
cancer
cell
line
lead
declin
mitochondri
membran
potenti
releas
cytochrom
c
cytoplasm
furthermor
effect
enhanc
activ
induc
apoptosi
wei
et
al
synthesis
seri
albiziabiosid
deriv
evalu
anticanc
potenti
vitro
vivo
target
lead
fig
show
signific
activ
cell
ic
moreov
triterpen
saponin
triazol
deriv
demonstr
favour
select
effect
multidrug
resist
mdr
cancer
cell
induc
ferroptosi
apoptosi
activ
via
mitochondri
pathway
vivo
investig
reveal
introduct
triazol
fragment
triterpen
skeleton
consider
inhibit
tumorigenesi
without
caus
toxic
normal
cell
inde
studi
provid
clinic
evid
support
consider
albiziabiosid
deriv
potenti
cancer
drug
candid
enhanc
activ
inform
novel
mechan
action
anoth
seri
saponin
hederacolchisid
arylamid
portion
synthesis
improv
inhibitori
activ
metabol
stabil
comprehens
determin
pharmacolog
mechan
antiprolif
activ
synthesis
analogu
assay
six
type
human
cancer
cell
line
cell
line
result
reveal
synthesis
hybrid
paraand
metasubstitu
demonstr
strong
cytotox
toward
cell
particular
deriv
fig
show
strong
anticanc
potenti
select
cell
compar
posit
control
hederacolchisid
moreov
result
cell
cycl
apoptosi
screen
indic
clearli
inhibit
prolifer
cell
via
induct
apoptosi
cell
cycl
arrest
phase
biolog
relev
natur
synthet
hybrid
compound
great
resourc
lead
format
develop
novel
pharmaceut
recent
novel
pharmacophor
relat
allogibber
acid
fragment
synthesis
wu
et
al
cytotox
potenti
hybrid
allogibber
triazol
hybrid
test
determin
anticanc
activ
cell
line
potent
compound
fig
demonstr
satisfactorili
higher
cytotox
posit
control
drug
cisplatin
toward
five
test
tumour
cell
line
ic
valu
mechanist
explor
reveal
hybrid
compound
induc
cell
cycl
arrest
phase
apoptosi
cell
quinin
deriv
contain
triazolylphenol
moieti
fig
identifi
select
hybrid
activ
cell
ic
addit
analogu
evalu
three
differ
solid
tumour
cell
line
one
normal
human
epitheli
cell
line
triazolebear
alkaloid
also
display
good
antiprolif
properti
cell
list
howev
may
lead
compound
colon
cancer
eight
time
potent
cisplatin
acetoxymethyl
compound
fig
synthesis
use
huisgen
azidealkyn
cycloaddit
synthet
analogu
natur
meiogynin
investig
panbcel
inhibitor
triazol
hybrid
induc
apoptosi
strongli
cytotox
cell
rate
respect
cell
note
select
target
protein
x
protein
bclxl
myeloid
cell
leukaemia
interact
new
triazol
hybrid
screen
use
fluoresc
polaris
result
indic
modul
later
chain
dramat
affect
compound
consider
modifi
activ
target
protein
triazolenatur
compound
hybrid
triterpen
derivativelink
moieti
prepar
anticanc
potenti
investig
select
cancer
cell
use
assay
hybrid
deriv
fig
display
signific
ic
valu
toward
human
glioblastoma
cell
line
nearli
higher
valu
refer
drug
cisplatin
novel
podophyllotoxin
hybrid
synthesis
use
click
chemistri
method
screen
dna
inhibitori
activ
well
anticanc
properti
aryl
triazolicamid
deriv
contain
chloro
fluoro
substitu
exhibit
satisfactori
cytotox
exampl
deriv
fig
show
promis
inhibit
select
human
cancer
cell
line
moreov
three
experiment
compound
display
ic
valu
cancer
cell
induc
apoptosi
prostat
cancer
cell
line
dna
topoisomeraseii
inhibit
assay
show
caten
dna
presenc
topoisomeras
ii
incub
compound
inhibit
topoisomeras
ii
activ
repres
presenc
connect
dna
well
howev
compound
demonstr
clear
linear
dna
synthesi
analog
etoposid
wellcharacteris
inhibit
topoii
wogoninbas
proteolysistarget
chimera
relat
moieti
develop
evalu
studi
mechan
action
degrad
protein
breast
cancer
cell
activ
triazol
hybrid
fig
ic
demonstr
better
antiprolif
potenti
cell
line
wogonin
ic
lower
concentr
western
blot
reveal
deriv
contain
triazol
linker
select
downregul
intracellular
level
sampl
identifi
select
lead
chemic
degrad
modest
antiprolif
potenti
variou
cancer
cell
line
decreas
level
prosurviv
protein
novel
deriv
bavachinincontain
synthesis
evalu
anticanc
effect
four
select
cancer
cell
line
result
analogu
fig
show
ic
valu
cancer
cell
line
respect
moreov
deriv
induc
apoptot
cell
death
morpholog
chang
inhibit
cell
migrat
coloni
format
quinazolin
quinazolinon
deriv
link
form
part
good
arsen
potenti
anticanc
agent
screen
cytotox
potenti
kb
cell
lenhatthuy
et
al
activ
compound
fig
ic
kb
respect
display
stronger
activ
posit
control
erlotinib
dock
simul
lead
compound
includ
activ
atpbind
site
variou
epiderm
growth
factor
receptor
egfr
kinas
conduct
interact
hbond
fragment
dens
hydrophobis
dioxygen
portion
quinazolin
remnant
atp
pocket
major
point
egfr
bind
phosphoinositid
properti
investig
via
vitro
cytotox
test
sever
cancer
cell
line
cell
two
compound
fig
demonstr
less
toxic
cell
ic
compound
specif
compound
variou
isoform
examin
use
western
blot
exhibit
select
isoform
ic
valu
respect
kettl
et
al
discov
quinazolinetriazol
conjug
fig
potenti
pankit
mutant
inhibitor
toward
gastrointestin
stromal
tumour
triazol
compound
contain
och
group
posit
expect
optim
balanc
kdr
select
kit
mutant
potenc
exhibit
potenti
growth
inhibit
kit
mutant
cell
line
satisfactori
kdr
margin
consider
improv
absorpt
distribut
metabol
elimin
adm
physicochem
properti
evalu
triazol
hybrid
mous
allograft
tumour
model
cell
show
caus
tumour
decreas
dose
mgkg
importantli
preclin
vivo
potenc
mark
encourag
may
serv
near
futur
treatment
patient
gastrointestin
stromal
tumour
peptidelik
deriv
oral
bioavail
howev
protein
therapi
tend
exhibit
specif
target
interact
greater
number
substanc
occur
expens
low
bioavail
metabol
instabl
introduct
ring
macromolecul
also
demonstr
interest
effect
use
connect
chen
et
al
synthesis
new
seri
nonpeptid
inhibitor
bear
two
moieti
toward
polobox
domain
pbd
pololik
kinas
among
compound
fig
relat
triazol
portion
show
consider
bioactiv
ic
valu
compar
report
phosphat
peptid
plhspt
ic
show
moder
activ
pbd
pololik
kinas
howev
author
suggest
nonpeptid
skeleton
may
confer
advantag
peptiderel
inhibitor
investig
novel
nonpeptid
pbd
pololik
kinas
inhibitor
could
lead
develop
select
anticanc
agent
matthiesen
et
al
report
new
seri
geranylgeranyl
diphosph
synthas
ggdp
inhibitor
base
isoprenoidtriazol
focus
grand
design
mask
neg
charg
bisphosphon
use
pivaloyloxymethyl
pom
group
use
ggdp
inhibitor
antimyeloma
agent
pomvers
compound
fig
display
augment
cellular
activ
conform
salt
nearli
improv
potenc
cao
et
al
report
leucineureidotriazol
conjug
synthesis
aminopeptidas
n
inhibitor
use
click
reaction
studi
compound
fig
exhibit
better
aminopeptidas
n
inhibit
compound
ic
approxim
lower
posit
control
bestatin
addit
compar
bestatin
show
favour
vitro
antiangiogenesi
potenc
huvec
tubular
structur
format
bioassay
rat
aortic
ring
model
furthermor
vivo
screen
exhibit
promis
antimetastasi
mous
pulmonari
metastasi
model
inhibitori
rate
bestatin
show
inhibit
antiprolif
activ
albuminbind
prodrug
fig
cell
line
treatment
show
affect
cell
viabil
elev
dose
nm
incub
alon
howev
combin
ic
valu
nm
chen
et
al
report
acridin
hydroxam
acid
dual
topo
hdac
inhibitor
prepar
deriv
exhibit
potent
antiprolif
potenti
toward
cell
activ
sampl
fig
display
nanomolar
ic
valu
cell
show
superior
inhibit
potenc
ic
nm
respect
severalfold
potent
hdac
posit
control
saha
ic
nm
respect
moreov
consider
activ
cleav
h
indic
induc
death
receptor
mitochondri
pathway
lead
apoptosi
novel
suggest
pgp
inhibitor
gao
et
al
follow
cytotox
revers
mdr
activ
bioassay
vitro
vivo
synthesis
sampl
demonstr
less
cytotox
ic
cell
howev
compound
fig
substitu
revers
mdr
concentrationdepend
manner
better
activ
verapamil
moreov
compound
significantli
reduc
ic
adriamycin
demonstr
strongest
revers
activ
close
tariquidar
revers
fold
hybrid
compound
contain
thiosemicarbazid
moieti
system
evalu
antiprolif
potenti
human
cancer
cell
line
cell
result
indic
compound
fig
potent
antiprolif
activ
ic
cell
respect
furthermor
mechanist
studi
reveal
cell
treat
compound
show
slight
inhibit
coloni
inhibit
indic
hybrid
inhibit
prolifer
cancer
cell
yamada
et
al
report
synthesi
antitumor
screen
target
compound
base
use
cuaac
ethynyldiphenylstiban
benzyl
azid
antitumor
activ
novel
synthesis
triazol
sampl
evalu
eight
cultur
tumour
cell
line
includ
human
solid
tumour
cell
line
colon
gastric
breast
tumour
among
fig
show
excel
antitumor
activ
test
tumour
cell
line
ic
cytotox
test
normal
cell
exhibit
higher
cytotox
analogu
particular
compound
fragment
exhibit
satisfactori
low
cytotox
toward
normal
cell
synthesi
characteris
cytotox
analysi
human
breast
cancer
cell
use
cuaac
reaction
perform
gilandoust
et
al
fig
demonstr
greatest
cytotox
select
breast
cancer
cell
line
ishikawa
cell
ic
valu
respect
thu
suggest
lead
cytotox
agent
cell
toxic
normal
lung
epitheli
cell
addit
downregul
express
cell
hybrid
compound
contain
pyrazolo
pyrimidinon
portion
evalu
glioma
cell
human
fig
inhibit
prolifer
cell
owe
good
solubl
dmso
chosen
evalu
flow
cytometri
assay
show
arrest
cell
phase
cell
cycl
indic
cell
unabl
duplic
dna
consequ
lead
reduct
mphase
cell
moreov
number
dead
cell
increas
increas
concentr
furthermor
western
blot
show
upregul
increas
concentr
confirm
involv
apoptosi
anticanc
activ
dasatinib
deriv
studi
leukaemia
leukaemia
progenitor
cell
line
among
triazolecontain
lead
compound
fig
show
superior
inhibitori
activ
ic
cell
line
follow
evalu
cell
use
coloni
form
cell
wound
scratch
bioassay
respect
dasatinibtriazol
hybrid
significantli
potent
dasatinib
surviv
rate
mice
dose
mgkg
daili
week
increas
dose
mice
treat
also
surviv
indic
low
toxic
compound
fig
discov
cmettarget
apoptosisinduc
agent
among
synthesis
thiopyrimidinetriazol
conjug
lead
compound
demonstr
greater
activ
posit
control
drug
foretinib
toward
cell
line
ic
valu
respect
furthermor
enzymebas
experi
show
select
inhibit
cmet
ic
nm
similar
foretinib
nm
moreov
induc
late
apoptosi
cell
concentrationdepend
manner
newli
synthesis
imidazopyridinetriazol
conjug
assay
cytotox
cancer
cell
line
mdamb
cell
activ
compound
fig
display
signific
antitumor
potenti
lung
cancer
cell
ic
valu
prostat
cancer
cell
line
effect
cell
cycl
cell
measur
use
flow
cytometri
h
treatment
caus
cell
cycl
arrest
g
phase
suggest
inhibit
tubulin
polymeris
antiprolif
properti
benzimidazoleteth
select
human
tumour
cell
line
hela
cell
evalu
compound
fig
exhibit
strong
select
antiprolif
potenti
cell
ic
valu
respect
select
elucid
mechan
action
compound
markedli
decreas
viabl
cell
popul
increas
earli
late
apoptoticprimari
necrot
cell
popul
respect
furthermor
compound
also
increas
earli
late
apoptoticprimari
necrot
cell
popul
respect
howev
viabl
cell
popul
decreas
enzym
mitogenactiv
protein
kinas
mapk
identifi
common
target
triazol
lead
inhibit
enzym
slightli
differ
activ
suggest
hybrid
deriv
contain
purin
two
portion
fig
inhibit
virul
candida
albican
exhibit
vitro
antiprolif
potenc
vivo
nontox
deriv
could
lead
compound
develop
avert
cancerassoci
biofilm
candida
infect
moreov
lead
compound
display
high
activ
peripher
blood
lymphoblast
ccrfcem
ec
modest
antineoplast
potenti
cell
line
ec
addit
lead
compound
select
c
albican
lg
r
mammalian
normal
cell
line
vero
vitro
ic
galleria
mellonella
vivo
anoth
hybrid
naphthoquinon
inhibit
cancer
cell
cell
well
normal
vero
cell
among
compound
fig
cell
viabil
cell
show
higher
select
vero
cell
select
index
si
confirm
potenti
deriv
druglik
candid
furthermor
hemocompat
studi
reveal
affect
platelet
aggreg
caus
arachidon
acid
activ
thromboplastin
time
indic
activ
blood
coagul
intrins
extrins
pathway
preserv
addit
demonstr
signific
haemolyt
profil
incub
h
confirm
good
safeti
profil
isoxazolebenzothiazolebenzoxazol
hybrid
prepar
anticanc
potenc
evalu
cancer
hela
cell
well
normal
cell
lead
compound
present
studi
compound
substitu
posit
isatin
portion
ethylpropyl
group
spacer
activ
exampl
best
lead
compound
exhibit
higher
potenc
tamoxifen
cell
use
hybrid
conjug
bioactiv
ligand
approach
fragment
deriv
investig
potenti
dual
inhibitor
cancer
chemotherapi
lead
compound
fig
exhibit
dual
inhibit
also
display
high
antiprolif
potenti
prostat
cancer
cell
line
excel
well
satisfactori
vivo
antiinflammatori
activ
ulcerogen
effect
addit
effect
tubulin
polymeris
reveal
compound
interf
microtubul
dynam
act
microtubuledestabilis
agent
schlapbach
et
al
report
novel
highli
select
proteas
inhibitor
base
deriv
relat
triazol
ring
jurkat
lymphoma
cell
line
hybrid
demonstr
activ
mechanist
cell
activ
assay
rga
suggest
possibl
use
inhibitor
treatment
diseas
autoimmun
disord
bcell
lymphoma
dysregul
pathway
note
parasubstitu
tether
moieti
detect
benefici
group
among
studi
substitu
compound
fig
addit
rat
pharmacokinet
show
high
vivo
clearanc
pyrimidinetriazol
hybrid
identifi
strong
effect
atpbind
cassett
subfamili
b
member
depend
mdr
modul
evalu
effect
mdr
revers
potenc
cell
paclitaxel
resist
show
compound
fig
exhibit
high
revers
potenti
approxim
higher
verapamil
posit
control
compound
effect
accumul
efflux
posit
control
increas
stockpil
decreas
efflux
cell
verapamil
p
among
deriv
fig
identifi
promis
anaplast
lymphoma
kinas
dual
inhibitor
ic
nm
ro
protooncogen
ic
nm
moreov
demonstr
signific
inhibitori
activ
ic
nm
anaplast
lymphoma
kinasedepend
ic
nm
ic
nm
cell
line
addit
acridin
orangeethidium
bromid
western
blot
assay
suggest
induc
cell
apoptosi
highli
inhibit
cellular
anaplast
lymphoma
kinas
activ
azol
particularli
triazol
sourc
sever
drug
antibacteri
antifung
agent
contrast
recent
discov
fuse
differ
heterocycl
triazol
exhibit
novel
antimicrobi
properti
exampl
fuse
pyridin
ring
investig
novel
lead
compound
develop
potenti
antimicrobi
agent
two
select
potenti
antibacteri
agent
fig
regioselect
synthesis
use
buchwald
strategi
nheteroaren
system
compound
display
zone
inhibit
bacillu
subtili
escherichia
coli
compar
mm
respect
streptomycin
hybrid
compound
display
zone
inhibit
mm
toward
b
subtili
e
coli
respect
triazolopyridin
exhibit
minimum
inhibitori
concentr
mic
similar
streptomycin
b
subtili
strain
et
al
investig
antibacteri
properti
target
toward
inhibit
eclepb
e
coli
spase
macrocycl
lipopeptid
contain
boron
ester
fragment
ring
peptid
fig
demonstr
activ
select
gramneg
bacteri
strain
howev
macrocycl
exhibit
lower
inhibit
eclepb
ic
nm
synthesis
triazolepeptid
wherea
contrast
macrocycl
exhibit
stronger
antibacteri
potenc
addit
peptid
also
screen
cell
evalu
cytotox
haemolyt
potenti
human
blood
result
indic
compound
cytotox
decreas
haemolysi
halv
ring
becom
one
major
antimicrobi
pharmacophor
effect
unit
wild
bacteri
photogen
clear
regard
set
dehydroacet
acidchalcon
deriv
synthesis
antimicrobi
evalu
hybrid
compound
contain
substitut
benzen
portion
exhibit
promis
activ
dehydroacet
acid
dehydroacet
acidchalcon
alkyn
among
deriv
fig
identifi
lead
compound
display
strong
activ
e
coli
mic
benzo
imidazo
thiazol
also
investig
potenti
antimicrobi
properti
compound
fig
demonstr
posit
anti
coli
antib
subtili
antisalmonella
typhi
antipseudomona
aeruginosa
potenc
show
low
mic
valu
mgml
notic
higher
posit
control
drug
norfloxacin
chloromycin
fluconazol
addit
interact
deriv
calf
thymu
dna
indic
hybrid
might
append
dna
form
complex
could
block
dna
replic
impart
consider
antimicrobi
activ
anoth
triazol
compound
fig
show
stronger
antifung
activ
toward
fungal
strain
aspergillu
niger
c
albican
synthesis
hybrid
zone
inhibit
mic
mm
c
albican
niger
respect
moreov
biosafeti
analysi
compound
sheep
blood
cell
also
indic
cytotox
mgml
set
hybrid
compound
tether
differ
fragment
biphenyl
amin
linker
synthesis
test
bacteri
transglycosylas
inhibitori
potenc
acinetobact
baumannii
transglycosylas
inhibitori
activ
synthesis
sampl
lower
compound
fig
show
much
higher
transglycosylas
inhibitori
activ
sampl
note
among
prepar
triazol
biphenyl
fragment
methylen
bridg
affect
activ
addit
compound
also
exhibit
good
antibacteri
potenc
staphylococcu
aureu
mic
anoth
deriv
studi
antibacteri
effect
sever
select
microorgan
includ
gramposit
strain
aureu
b
subtili
aureu
pr
gramneg
pathogen
klebsiella
pneumonia
e
coli
oxi
phenyl
fig
identifi
lead
compound
aureu
b
subtili
aureu
pr
k
pneumonia
respect
collect
report
indic
potenti
progress
moieti
termin
amidemimet
element
maintain
modul
amideteth
bioactiv
ncoumaroyltyramin
link
triazol
ring
investig
potenti
lead
compound
posit
control
bacteri
biofilm
control
three
gramneg
strain
pseudoalteromona
ulva
pseudoalteromona
lipolytica
paracoccu
sp
speci
select
abil
form
biofilm
och
substitu
tyramin
fragment
affect
potenc
deriv
fig
display
best
antibiofilm
activ
effect
ampicillin
speci
ampicillin
quinazolinon
link
moieti
show
superior
antibacteri
potenti
mdr
aureu
compound
fig
possess
specif
strong
potenc
aureu
mic
ml
inact
gramneg
pathogen
baumannii
e
coli
mic
addit
hybrid
compound
surmount
mdr
mechan
exhibit
highli
potent
inhibitori
effect
mdr
aureu
includ
strain
resist
vancomycin
mic
valu
target
compound
fig
contain
och
naphthalen
fragment
demonstr
uniqu
activ
bacteri
strain
b
subtili
staphylococcu
epidermidi
p
aeruginosa
e
coli
well
fungal
speci
c
albican
aspergillu
niger
mic
valu
moieti
chalcon
fragment
clearli
synergis
biolog
activ
conjug
pharmacophor
unit
indic
synergist
properti
addit
dock
simul
e
coli
topoisomeras
ii
dna
gyras
b
show
triazolechalcon
conjug
may
feasibl
inhibit
dna
topoisomeras
indoletriazol
hybrid
fig
name
n
butanamid
found
promis
quorum
sens
inhibitori
activ
p
aeruginosa
among
synthesis
sar
analysi
show
ethyl
group
posit
four
aryl
portion
posit
affect
activ
wherea
group
bromo
br
deriv
exhibit
moder
activ
set
tether
benzhydrylpiperazin
fragment
assay
antibacteri
potenti
aureu
e
coli
use
agar
well
diffus
method
triazol
deriv
fig
found
activ
ciprofloxacin
zone
inhibit
mm
aureu
mm
ecoli
respect
combin
ring
benzhydrylpiperazin
moieti
increas
biolog
activ
demonstr
modif
benzhydrylpiperazin
scaffold
contain
portion
could
feasibl
strategi
develop
antibacteri
agent
sever
microb
bacteri
fungal
strain
includ
epidermidi
b
subtili
p
aeruginosa
e
coli
c
albican
niger
select
analys
inhibitori
activ
scaffold
synthesis
compound
fig
display
equal
antimicrobi
activ
select
strain
mic
except
niger
anoth
lead
deriv
fig
show
compar
antimicrobi
potenti
microbi
speci
mic
except
niger
b
subtili
introduct
halogen
substitu
thiophenylbenzyl
fragment
found
increas
inhibitori
potenc
moghimi
et
al
synthesis
triazolelink
aryl
urea
hybrid
ureas
inhibitor
toward
ureolyt
bacteri
infect
dichlorocontain
triazol
compound
fig
demonstr
superior
activ
ic
assay
indic
ureas
inhibitor
compound
bear
substitu
accept
adm
properti
suggest
attract
candid
design
modif
search
novel
ureas
inhibitor
quinolon
conjug
also
assay
antibacteri
screen
follow
select
bacteri
strain
streptococcu
pyogen
aureu
e
coli
p
aeruginosa
salmonella
typhi
compound
fig
bear
aryl
fragment
demonstr
high
antibacteri
potenc
select
aureu
well
salmonella
typhi
c
moreov
statist
twodimension
quantit
sar
model
valid
remark
admet
activ
compound
among
prepar
sampl
triazol
infrequ
evalu
antitubercular
properti
contrast
conjug
divers
heterocycl
fragment
report
demonstr
potenti
antitubercular
properti
exampl
contain
coumarin
moieti
assay
antimycobacteri
activ
mycobacteri
dihydrofol
reductas
mtb
dhfr
inhibit
among
compound
fig
display
strong
antimycobacteri
potenc
mic
mycobacterium
bovi
bcg
synthesis
analogu
compound
also
demonstr
antitubercular
activ
mic
valu
mycobacterium
tuberculosi
cytotox
two
sampl
examin
cell
line
wherea
low
haemolyt
activ
confirm
use
red
blood
cell
studi
show
exhibit
higher
bind
affin
mtb
dhfr
human
dhfr
investig
agreement
select
observ
enzym
inhibit
assay
spain
et
al
investig
cu
zn
complex
triazolecyclam
bear
ligand
activ
virul
drugresist
tuberculosi
strain
sar
analys
cyclam
compound
cyclic
cyclam
fragment
tether
two
equal
naphthalimid
pendant
triazol
linker
studi
compound
fig
exhibit
good
water
solubl
reduc
bacteri
load
vivo
note
zebrafish
embryo
use
investig
vivo
toxic
rang
dose
complex
use
embryo
surviv
assay
recent
alkoxytriazolequinolon
fig
mic
respect
found
activ
compound
tuberculosi
moreov
exhibit
ic
valu
compar
ciprofloxacin
screen
tuberculosi
dna
gyras
use
dna
supercoil
activ
bioassay
compar
clinic
strain
includ
mdr
compound
show
similar
potenc
exhibit
ciprofloxacinresist
strain
howev
case
ciprofloxacin
may
higher
vitro
inhibitori
activ
tuberculosi
dna
gyras
deriv
seri
contain
isatinmoxifloxacin
hybrid
synthesis
evalu
antituberculosi
properti
anoth
triazol
deriv
fig
n
c
synthesis
use
cuaac
also
found
promis
antim
tuberculosi
agent
h
rv
strain
mic
mdr
clinic
isol
mic
note
author
envis
coumarin
triazol
fragment
conjug
och
bridg
would
possess
greater
pliabl
molecul
bind
need
expect
target
furthermor
minimum
bactericid
concentr
mbc
triazol
conjug
also
determin
result
reveal
conjug
contain
oh
group
demonstr
low
potenc
mbc
posit
control
isoniazid
mdr
clinic
isol
moreov
assay
activ
test
vitro
antitubercular
properti
triazoleindol
hybrid
deriv
evalu
tuberculosi
activ
dormant
state
activ
compound
fig
show
superior
antitubercular
potenc
tuberculosi
dormant
ic
mic
valu
respect
base
sar
observ
presenc
br
substitu
indol
portion
deriv
brrelat
indoletriazol
conjug
confer
significantli
higher
potenc
unsubstitut
bisindoletriazol
antimycobacteri
evalu
spirochromen
scaffold
conduct
use
micropl
alamar
blue
assay
result
reveal
condens
spirochromen
show
modest
good
potenc
compound
fig
demonstr
excel
activ
respect
tuberculosi
strain
dipeptidyl
nitril
bear
moieti
evalu
structuredivers
design
point
view
search
select
trypanocid
rhodesain
inhibitor
among
compound
fig
demonstr
interest
activ
inhibit
cell
growth
trypanosoma
brucei
rhodesiens
follow
incub
h
ic
addit
author
also
studi
pharmacokinet
properti
synthesis
compound
evalu
mechan
action
compar
brain
penetr
cell
macrocycl
seri
interestingli
efflux
ratio
improv
human
mous
compar
respect
exhibit
lead
macrocycl
seri
imidazoletriazol
hybrid
bear
substitu
along
styryl
fragment
exhibit
antiamoeb
potenc
target
compound
fig
contain
fragment
describ
found
activ
entamoeba
histolytica
among
metronidazoletriazolestyryl
hybrid
analogu
natur
lignan
name
methyl
isoxazol
fig
also
identifi
lead
compound
antiparasit
activ
lead
hybrid
prepar
sampl
inhibit
leukaemia
cell
infect
trypanosoma
cruzi
amastigot
vitro
assay
reveal
potenc
deriv
equal
posit
control
benznidazol
gi
si
observ
introduct
hydrophob
compound
increas
potenc
pliabl
properti
pentylmoieti
may
interact
hydrophob
side
molecular
target
addit
synthesis
compound
includ
triazol
assay
amastigot
leishmania
amazonensi
signific
result
obtain
even
antitoxoplasma
activ
synthesis
arctigenin
scaffold
bear
ring
evalu
vitro
vivo
lead
compound
fig
display
strong
vitro
antitoxoplasma
gondii
activ
less
cytotox
ic
gondii
hela
cell
line
respect
si
indic
promis
result
arctigenin
spiramycin
addit
pharmacolog
bioassay
suggest
also
lead
partial
tachyzoit
malform
p
suggest
arctigeninderiv
compound
potenti
antiparasit
druglik
unit
warrant
indepth
mechanist
develop
malaria
still
remain
one
deadli
diseas
world
natur
synthet
success
use
malaria
medicin
chemistri
et
al
synthesis
naphthoquinonolylteth
hybrid
use
cuaac
base
lapachol
modif
antiplasmodi
potenti
malaria
report
hybrid
product
assay
chloroquineresist
plasmodium
falciparum
cell
line
among
sever
deriv
particular
compound
fig
ic
si
exhibit
stronger
antimalari
potenc
select
lapachol
ic
si
hybrid
bear
pyrimidinechloroquinolin
screen
antiplasmodi
potenti
chloroquinesensit
strain
p
falciparum
lead
compound
fig
ic
demonstr
excel
activ
superior
si
ic
vero
cell
note
sar
analysi
reveal
natur
substitu
triazolelink
pyrimidin
core
case
pnitro
group
obvious
enhanc
antiplasmodi
properti
antiplasmodi
activ
novel
coumarintriazol
hybrid
fig
evalu
chloroquinesensit
strain
p
falciparum
exhibit
higher
activ
ic
mgml
lead
compound
contain
two
electrondon
och
substitu
benzen
portion
appar
affect
antimalari
activ
addit
effect
supercoil
potenc
dna
gyras
relax
plasmid
dna
inhibit
supercoil
activ
could
attribut
prevent
atp
hydrolysi
need
inhibit
gyras
dna
bind
enzymat
cycl
triazolelink
glycohybrid
isatin
hydrazon
synthesis
develop
compound
antimalari
potenti
antiplasmodi
properti
deriv
fig
diacetonid
galactos
analogu
sugar
portion
exhibit
equal
activ
lead
compound
och
leishmaniasi
one
public
health
problem
treatment
quit
challeng
concern
emerg
resist
strain
address
issu
novel
hybrid
compound
bear
thiosemicarbazon
moieti
identifi
temraz
et
al
evalu
antileishmani
potenti
notabl
hybrid
fig
demonstr
nanomolar
activ
leishmania
major
promastigot
ic
nm
axen
amastigot
ic
valu
indic
higher
activ
miltefosin
vivo
acut
toxic
test
reveal
toxic
treatment
lead
compound
liver
lung
spleen
kidney
isol
mice
administ
mgkg
fig
investig
synthet
pathway
antiparasit
activ
eugenol
natur
compound
base
compound
tether
ring
consid
leishmanicid
effect
eugenol
compound
studi
shown
antileishmani
activ
compound
propyl
fig
found
activ
ic
l
triazolelink
eugenol
deriv
also
assay
leishmania
parasit
periton
macrophag
ic
l
show
effect
cell
viabil
cytotox
potenti
macrophag
cell
evidenc
ic
l
si
addit
triazol
deriv
demonstr
higher
effect
pentamidin
glucantim
drug
use
clinic
antileishmani
research
heterocycl
contain
quinolon
skeleton
synthes
triazol
hybrid
synthesis
evalu
intracellular
amastigot
extracellular
promastigot
luciferas
express
leishmania
donovani
methyl
fig
exhibit
promis
antiamastigot
potenc
ic
deriv
synthesis
deriv
prepar
vivo
assay
effect
compound
golden
hamster
model
evalu
mg
kg
administ
intraperiton
consecut
day
triazol
exhibit
continu
activ
parasit
inhibit
treatment
day
suggest
triazolebas
dipeptid
contain
leucin
moieti
fig
promis
antileishmani
activ
ic
valu
calcul
base
normal
growth
inhibit
ic
valu
leishmania
major
promastigot
relev
factor
cytotox
lipophil
antiparasit
activ
lead
compound
substanti
point
design
new
antileishmani
agent
furthermor
dipeptid
lipophil
prepar
dipeptid
investig
notwithstand
exist
variou
type
antivir
drug
clinic
treatment
human
immunodefici
viru
hiv
acquir
immun
defici
syndrom
aid
still
remain
increas
challeng
public
health
therefor
hybrid
identifi
lead
candid
indic
superior
effect
divers
viral
type
antihepat
b
viru
hbv
properti
novel
hybrid
scaffold
studi
liu
et
al
observ
triazol
compound
fig
promis
antivir
potenti
impress
activ
lamivudineresist
hbv
mutant
also
screen
hbvinfect
duck
model
result
show
serum
liver
duckhbv
dna
level
clearli
decreas
treatment
seri
fuse
heterocycl
antivir
properti
explor
karypid
et
al
synthesis
hybrid
test
sever
type
virus
hiv
type
herp
simplex
virus
type
tk
adeno
coronaviru
vaccinia
viru
valu
compar
appropri
posit
control
drug
zidovudin
brivudin
cidofovir
ganciclovir
acyclovir
alovudin
urtica
dioica
agglutinin
zalcitabin
howev
antivir
assay
indic
major
compound
slight
activ
select
virus
among
deriv
fig
ec
valu
averag
activ
compound
human
coronaviru
display
nearli
lower
inhibitori
potenc
urtica
dioica
agglutinin
ec
pentacycl
iminosugar
compound
construct
fuse
triazolo
oxazepin
scaffold
investig
hiv
reversetranscriptas
inhibitori
potenti
synthesis
sampl
demonstr
inhibitori
activ
reversetranscriptas
particular
deriv
fig
display
ic
valu
reversetranscriptas
identifi
lead
compound
anoth
triazol
compound
fig
synthesis
replac
pyridazin
moieti
ring
suggest
potenti
nonnucleosid
inhibitori
activ
hepat
c
viru
hvc
compound
show
ec
nm
cc
nm
cellbas
hcv
replicon
system
experi
respect
potenc
pharmacokinet
hybrid
molecul
contain
triazol
dihydropyrimidinon
ring
synthesis
via
huisgen
azidealkyn
cycloaddit
evalu
human
varicellazost
viru
activ
hybrid
fig
demonstr
strong
antivir
potenti
ec
tk
varicella
zoster
viru
vzv
strain
decreas
tkstrain
addit
note
replac
benzyl
fragment
benzyl
case
enhanc
antivir
potenc
tk
vzv
strain
consider
reduc
cell
growth
inhibit
antivir
activ
investig
novel
deriv
obtain
cuaac
ca
protein
inhibitor
show
deriv
fig
show
superior
potenc
ec
fig
show
equal
promis
potenc
mutant
strain
howev
also
demonstr
lower
cytotox
deriv
compound
also
evalu
possibl
inhibitori
activ
revers
transcriptas
display
averag
inhibitori
potenc
ic
respect
approxim
less
potent
refer
drug
etravirin
nevertheless
suggest
lead
compound
nonnucleosid
revers
transcriptas
inhibitor
possess
fragment
triazol
portion
fig
identifi
superior
lead
compound
antidiabet
properti
inhibit
competit
manner
ki
valu
dock
studi
lead
compound
confirm
welldock
activ
site
fig
exhibit
activ
target
enzym
best
among
synthesis
triazol
deriv
ic
valu
inhibit
enzym
moreov
molecular
model
analysi
reveal
display
preferenti
bind
mode
interact
three
activ
site
residu
suggest
develop
may
provid
new
lead
compound
antidiabet
drug
neuroprotect
one
challeng
aspect
current
medic
research
develop
treatment
neurolog
disord
includ
alzheim
parkinson
huntington
diseas
furthermor
design
synthesi
modif
neuroprotect
agent
base
hybrid
remain
import
research
direct
recent
year
bear
longanlacton
analogu
synthesis
potenti
enhanc
neurotroph
activ
vitro
cell
cytotox
potenti
synthesis
natur
product
deriv
examin
mous
neuroblastoma
cell
among
deriv
fig
demonstr
strong
neurotroph
activ
cell
confirm
batteri
cellbas
neurit
outgrowth
assay
deriv
distinctli
increas
neurit
length
compar
dimethyl
sulfoxid
dmso
lou
gehrig
diseas
also
known
amyotroph
later
sclerosi
al
neurolog
maladi
central
nervou
system
cn
patholog
includ
progress
loss
motor
neuron
cn
control
motor
function
normal
lead
death
within
year
diagnosi
use
set
triazoleriluzolehybrid
novel
motor
neuron
screen
approach
sweeney
et
al
identifi
sever
novel
triazol
neuroprotect
agent
deriv
substitu
tether
pyridyl
fragment
compound
fig
demonstr
higher
neuroprotect
potenc
riluzol
two
independ
vitro
bioassay
primari
neuron
gammaaminobutyr
acid
gaba
import
inhibitor
neurotransmitt
cn
regard
giraudo
et
al
investig
deriv
bear
hydroxi
oh
substitu
moieti
promis
biomimet
gaba
inhibitor
author
studi
synthesis
triazol
receptor
bind
research
determin
bind
affin
deriv
nativ
gaba
receptor
use
rat
brain
membran
prepar
pharmacolog
assay
reveal
diphenylpropylsubstitut
lead
compound
fig
show
higher
ki
valu
molecular
model
analysi
show
adopt
bind
pose
triazol
portion
orient
addit
author
suggest
alkyl
triazol
molecul
potenti
strategi
develop
heterocycl
system
activ
gaba
receptor
novel
fuse
triazol
triazolo
pyridin
deriv
synthesis
receptor
antagonist
chrovian
et
al
lead
fig
increas
plasma
free
fraction
exhibit
potenti
receptor
occup
hippocampu
rat
low
ed
valu
mgkg
unbound
plasma
ec
valu
ngml
moreov
suppress
brain
interleukin
il
releas
vivo
freeli
move
rat
challeng
agonist
bzatp
addit
hybrid
deriv
notabl
solubl
show
good
toler
preclin
studi
result
accept
cardiovascular
safeti
profil
vivo
addit
lead
compound
select
candid
investig
clinic
trial
phase
evalu
safeti
toler
healthi
human
toward
develop
treatment
mood
disord
luo
et
al
synthesis
sever
oxadiazoletriazol
hybrid
activ
receptor
effect
neuroinflammatori
diseas
cn
radiosynthesis
sampl
fig
subject
primari
screen
test
permeabl
across
bloodbrain
barrier
rodent
vivo
high
receptor
bind
potenc
ic
nm
observ
satisfactori
radiochem
yield
high
radiochem
puriti
nearli
specif
activ
show
defluorin
vivo
volinanserin
also
known
strong
receptor
antagonist
treatment
diseas
sleep
disord
schizophrenia
gilbertson
et
al
synthesis
activ
select
volinanserin
enantiom
along
seri
deriv
contain
ring
evalu
elucid
develop
activ
cn
howev
investig
prepar
sampl
exert
antagonist
abil
bival
ligand
howev
although
compound
fig
pic
ic
nm
exhibit
less
activ
parent
compound
volinanserin
pic
ic
nm
compound
exhibit
compar
activ
recent
synthesis
seri
bival
ligand
bear
sever
ethylen
glycol
linker
novel
seri
acid
conjug
investig
neuroprotect
antiacetylcholinesteras
antiach
activ
multitargetdirect
ligand
treatment
alzheim
diseas
specif
compound
fig
identifi
potenti
ach
inhibitor
display
satisfactori
inhibit
peptid
aggreg
addit
deriv
show
select
biomet
chelat
protect
intracellular
ro
format
well
neuroprotect
h
cytotox
evalu
neuroprotect
effect
use
hybridis
approach
anoth
benzo
f
coumarin
fig
synthesis
identifi
activ
deriv
ic
valu
ach
butyrylcholinesteras
buch
steadyst
inhibit
assay
show
high
concentr
deriv
show
increas
inhibitori
potenc
novel
sarsasapogenintriazolyl
hybrid
prepar
report
promis
antialzheim
agent
hybrid
screen
aggreg
inhibitori
potenti
sever
deriv
includ
fig
posit
control
curcumin
show
high
activ
inhibit
format
fibril
moder
neuroprotect
activ
hydrogen
peroxid
h
induc
neurotox
cell
target
alzheim
diseas
inhibitori
effect
seri
novel
compound
investig
electrophoru
electricu
ach
hors
serum
bche
among
synthesis
deriv
hybrid
fig
strongli
inhibit
ach
bche
ic
valu
concentr
respect
note
although
inhibit
cholinesteras
compound
slightli
lower
posit
control
drug
tacrin
uniqu
bind
mode
suggest
appropri
analysi
made
lead
compound
develop
novel
dual
inhibitor
ach
bche
novel
compound
synthesis
use
huisgen
azidealkyn
cycloaddit
identifi
new
antiinflammatori
agent
target
lox
inhibit
among
fig
inhibit
ic
valu
respect
inhibit
analysi
show
ic
valu
respect
inhibit
valu
three
compound
compar
celecoxib
diclofenac
indomethacin
inhibit
rate
compar
zileuton
meclofenam
sodium
refer
drug
addit
inhibit
monocyt
macrophag
differenti
effici
ic
ic
diclofenac
sodium
challeng
pmainduc
differenti
assay
hybrid
tether
hosubstitu
phenylsulfon
fragment
posit
synthesis
antiinflammatori
properti
studi
focus
assay
proinflammatori
cytokin
tumour
necrosi
factor
tnf
lipopolysaccharid
lp
stimul
cell
line
potent
compound
fig
potent
suppress
ic
valu
lpsstimul
cell
moreov
evalu
inhibitori
activ
osteoclastogenesi
raw
cell
mechan
action
studi
show
hybrid
deriv
display
dosedepend
inhibit
osteoclastogenesi
suppress
nfkb
pathway
stimul
consider
enhanc
phosphoryl
nfkb
ser
ser
ser
lead
compound
dosedepend
decreas
phosphoryl
yu
et
al
report
activ
modifi
r
antagonist
reduct
inflamm
observ
compound
exhibit
potent
antagonist
properti
fig
fluoresc
assay
three
ch
chain
two
amin
tether
thiophen
ring
via
amid
linker
f
pet
tracer
fig
identifi
potenti
carbon
anhydras
ix
caix
inhibitor
vitroin
vivo
bioassay
mechan
action
report
et
al
author
began
vivo
experi
inject
lead
compound
caix
express
skin
cell
evalu
effect
pet
tracer
absorpt
cell
line
particular
evalu
activ
compound
caix
inhibitor
show
distribut
bodi
mice
harvest
variou
bodi
organ
biodistribut
assay
also
carri
result
reveal
sampl
localis
tumour
trace
amount
mostli
accumul
intestin
tumour
type
pharmacokinet
evalu
assess
distribut
coeffici
vivo
stabil
balbc
mice
vitro
stabil
human
serum
benzenesulfonamid
deriv
contain
moieti
evalu
potenti
carbon
anhydras
properti
isoform
caiix
inhibit
rate
target
compound
compar
acetazolamid
clinic
use
posit
control
drug
newli
synthesis
deriv
exhibit
superior
ki
valu
nm
ca
effect
tumourassoci
isoform
weaker
refer
drug
moder
deriv
fig
demonstr
excel
inhibitori
potenc
glaucomaassoci
ca
iv
k
nm
compar
acetazolamid
gener
understood
sulphonamid
bear
scaffold
import
ca
inhibitor
therefor
strategi
use
develop
novel
benzenesulfonamid
bear
moieti
screen
caiix
inhibit
stop
flow
carbon
dioxid
hydrat
assay
synthesis
sampl
highli
inhibit
cytosol
isoform
cai
display
ki
valu
nm
regard
investig
tumourassoci
transmembran
isoform
caix
deriv
fig
demonstr
better
inhibit
acetazolamid
ki
nm
wu
et
al
suggest
triazol
compound
fig
highli
potent
candid
treatment
renal
anaemia
confirm
activ
hifphd
inhibitor
ic
nm
higher
roxadustat
ic
nm
furthermor
vivo
biolog
assay
reveal
upregul
haemoglobin
cisplatininduc
anaem
mice
gl
normal
level
gl
obviou
toxic
indoletriazol
hybrid
synthesis
use
click
method
studi
antiadipogen
properti
studi
n
methyl
methyl
benzenesulfonamid
fig
identifi
promis
antiadipogen
agent
ic
potent
parent
compound
evalu
reveal
antiadipogen
activ
lead
compound
evid
earli
stage
adipogenesi
mitot
clonal
expans
control
phase
cell
cycl
arrest
mechanist
investig
reveal
hybrid
deriv
exhibit
antiadipogen
properti
activ
pathway
adipogen
gene
moreov
show
correl
decreas
increas
express
epididym
white
adipos
tissu
vivo
seri
newli
functionalis
isoquinolin
synthesis
antioxid
screen
vitro
antioxid
activ
analysi
dpph
method
reveal
compound
fig
exhibit
stronger
antioxid
potenc
ic
valu
posit
control
drug
trolox
higher
activ
posit
control
drug
trolox
note
common
deriv
tether
electronwithdraw
substitu
f
cl
triazol
moieti
pyrimidoisoquinolin
system
show
averag
high
antioxid
properti
sever
coumarinopyrazol
compound
synthesis
evalu
ach
antityrosinas
anticanc
potenti
triazol
regioisom
fig
demonstr
satisfactori
activ
target
bioassay
exampl
antibch
activ
result
show
trichlorinerel
compound
activ
synthesis
cycloadduct
activ
assay
show
observ
ie
display
strong
activ
ic
valu
respect
antityrosinas
activ
assay
two
cycloadduct
show
less
activ
sampl
howev
compound
ic
show
highest
cytotox
cell
among
evalu
tether
coumarinopyrazol
conjug
miscellan
activ
disaccharid
investig
rnase
inhibitor
first
time
kayet
et
al
suggest
except
linker
type
action
triazol
moieti
carbohydr
azol
could
direct
sugar
fragment
bind
site
enzym
biophys
assay
reveal
compound
fig
decreas
ribonucleolyt
potenc
effici
wherea
deriv
fig
also
exhibit
higher
inhibitori
activ
agaros
gel
electrophoresi
prepar
compound
miss
cooh
substitu
kinet
studi
show
triazol
hybrid
weaker
rnase
activ
ki
homolog
ki
confirm
introduc
carboxyl
function
group
posit
furanos
ring
decreas
ki
valu
kozarski
et
al
report
set
phosphat
substanc
bear
ring
posit
promis
inhibitor
human
cniiib
among
four
prepar
analogu
compound
fig
inhibit
cniiib
potenc
ic
valu
three
substanc
inact
moreov
effect
studi
human
decap
scaveng
enzym
hdcp
result
reveal
despit
slight
inhibitori
potenc
hdcp
less
phosphat
identifi
select
inhibitor
hs
cniiib
simpl
biochem
assay
peterson
et
al
prepar
symmetr
thiodigalactosid
deriv
carri
aryltriazolyl
portion
optimis
bind
near
introduct
addit
fluorin
phenyltriazol
ring
produc
lead
hybrid
fig
thiodigalactosid
slightli
increas
affin
improv
select
benzamid
scaffold
link
ring
discov
promis
human
dihydroorot
dehydrogenas
hdhodh
inhibitor
lu
et
al
hdhodh
inhibitor
play
import
role
ratelimit
step
pyrimidin
biosynthesi
pyrimidin
play
critic
role
dna
rna
biosynthesi
studi
potent
compound
fig
display
superior
suppress
hdhodh
ic
immunosuppress
assay
reveal
also
potent
inhibit
prolifer
activ
peripher
blood
mononuclear
cell
syeda
et
al
describ
new
ouabagenin
triazol
analogu
develop
safe
male
contracept
select
promis
inhibitor
na
katpas
sperm
function
result
show
compound
fig
specif
target
na
katpas
activ
lead
deriv
determin
rat
sperm
vm
ph
ca
prepar
cell
sampl
treat
presenc
absenc
h
sperm
vm
ph
ca
measur
use
variou
fluorophor
deriv
caus
sperm
plasma
membran
depolaris
escal
vm
almost
caus
intracellular
sperm
acidif
overal
except
decreas
abil
sperm
swim
reach
egg
demonstr
decreas
hyperact
sperm
movabl
potenti
activ
could
serv
futur
develop
drug
candid
male
contracept
sever
inhibitor
autotaxin
use
determin
bind
mode
known
inhibitor
exampl
develop
thomson
et
al
modif
result
show
replac
benzoxazolon
fragment
triazol
zincbind
motif
decreas
crystallin
increas
solubl
among
agent
compound
fig
select
high
affin
conclus
lead
compound
contain
moieti
serv
effect
drug
candid
current
form
follow
appropri
chemic
biolog
modif
futur
inde
develop
cuaac
gener
broad
profil
activ
present
review
show
synthesis
triazol
favour
activ
motif
act
linker
show
interact
enzym
also
direct
appropri
sider
fuse
ring
triazol
hybrid
system
bind
site
enzym
amino
acid
properti
triazol
hybrid
molecul
make
uniqu
motif
import
factor
drug
design
deliveri
although
select
solubl
common
triazolehybrid
well
improv
vivo
assay
result
indic
develop
need
also
focu
fuse
heterocycl
compound
triazol
linker
well
studi
mechan
action
clear
exampl
propos
ring
insert
instead
imidazol
portion
purin
skeleton
type
fuse
pyrimidin
may
exhibit
interest
properti
medicin
chemistri
addit
present
review
indic
proport
studi
dedic
coumarin
modif
use
cuaac
method
futur
believ
elucid
chemistri
biolog
would
facilit
develop
lead
compound
lower
toxic
higher
select
